 DUBLIN, Ireland, July 27, 2020 GLOBE NEWSWIRE -- Avadel Pharmaceuticals plc Nasdaq: AVDL announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Companys financial results for the second quarter ended June 30, 2020. To access the conference call, investors are invited to dial 877-407-9716 U.S. and Canada or 201-493-6779 international. The conference ID number is 13707645. A live audio webcast can be accessed by visiting the investor relations section of the Companys website, A replay of the webcast will be archived on Avadels website for 90 days following the event.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc Nasdaq: AVDL is an emerging biopharmaceutical company. The Companys primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness EDS and cataplexy. For more information, please visit Investor Contacts Tom McHugh Chief Financial Officer Phone: 636 449-1843 Email: Tim McCarthy LifeSci Advisors, LLC Phone: 212 915.2564 Email: Media Contact Patrick Bursey LifeSci Communications, LLC Phone: 646 970-4688 Email: 